ES2116298T3 - Nuevo metodo de tratamiento de la depresion. - Google Patents

Nuevo metodo de tratamiento de la depresion.

Info

Publication number
ES2116298T3
ES2116298T3 ES91918381T ES91918381T ES2116298T3 ES 2116298 T3 ES2116298 T3 ES 2116298T3 ES 91918381 T ES91918381 T ES 91918381T ES 91918381 T ES91918381 T ES 91918381T ES 2116298 T3 ES2116298 T3 ES 2116298T3
Authority
ES
Spain
Prior art keywords
new method
depression treatment
depression
treatment
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91918381T
Other languages
English (en)
Inventor
Jan David Wallace
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of ES2116298T3 publication Critical patent/ES2116298T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN NUEVO USO DE AMINOACIDOS CICLICOS CONOCIDOS. TALES COMPUESTOS, QUE INCLUYEN GABAPENTINA, SON UTILES PARA EL TRATAMIENTO DE TIPOS DE DEPRESION DE MAYOR Y MENOR IMPORTANCIA.
ES91918381T 1990-10-12 1991-10-02 Nuevo metodo de tratamiento de la depresion. Expired - Lifetime ES2116298T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/596,270 US5025035A (en) 1990-10-12 1990-10-12 Method of treating depression

Publications (1)

Publication Number Publication Date
ES2116298T3 true ES2116298T3 (es) 1998-07-16

Family

ID=24386662

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91918381T Expired - Lifetime ES2116298T3 (es) 1990-10-12 1991-10-02 Nuevo metodo de tratamiento de la depresion.

Country Status (11)

Country Link
US (1) US5025035A (es)
EP (1) EP0552240B1 (es)
JP (1) JP3192141B2 (es)
AT (1) ATE164065T1 (es)
CA (1) CA2092416A1 (es)
DE (1) DE69129115T2 (es)
DK (1) DK0552240T3 (es)
ES (1) ES2116298T3 (es)
GR (1) GR3026519T3 (es)
MX (1) MX9101526A (es)
WO (1) WO1992006686A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
UA49011C2 (uk) * 1996-03-14 2002-09-16 Варнер-Ламберт Компані Похідні циклічної амінокислоти, фармацевтична композиція та спосіб лікування
US6372792B1 (en) 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
US6194459B1 (en) 1997-08-19 2001-02-27 Warner-Lambert Company Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotors stimulants
WO1999018063A2 (en) 1997-10-07 1999-04-15 Warner-Lambert Company Process for preparing a cyclic amino acid anticonvulsant compound
HUP0004310A3 (en) * 1997-10-27 2001-11-28 Warner Lambert Co Cyclic amino acids, and derivatives thereof and pharmaceutical compositions comprising the said compounds as active agents
CA2327285C (en) * 1998-05-15 2005-06-14 Warner-Lambert Company Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
ID26395A (id) * 1998-05-15 2000-12-21 Warner Lambert Comapny Turunan asam gamma-aminobutirat yang mengandung komposisi padat dan proses pembuatannya
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
DK1169060T3 (da) * 1999-04-09 2006-01-16 Euro Celtique Sa Natriumkanalblokkerpræparater og anvendelse deraf
NZ514401A (en) * 1999-04-09 2003-10-31 Warner Lambert Co Combinations of GABA analogs and tricyclic compounds to treat depression
AP2002002501A0 (en) * 1999-10-07 2002-06-30 Warner Lambert Co Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
IL153398A0 (en) 2000-06-16 2003-07-06 Teva Pharma Stable gabapentin containing more than 20 ppm of chlorine ion
DK1423168T3 (da) * 2001-09-03 2006-05-15 Newron Pharm Spa Farmaceutisk præparat omfattende gabapentin eller en analog deraf og et alfa-aminoamid og dets analgetiske anvendelse
ITMI20012750A1 (it) 2001-12-21 2003-06-21 Procos Spa Processo per la produzione dell'acido 1-(amminometil)-cicloesil-acetico in forma pura
US20030119908A1 (en) * 2001-12-21 2003-06-26 Zambon Group S.P.A. Stable gabapentin compositions
US20050181071A1 (en) * 2004-02-18 2005-08-18 Binder Michael R. Method for the treatment of clinical depression
DK1809271T5 (da) * 2004-09-10 2010-12-06 Newron Pharm Spa Anvendelse af (R)-(halogenbenzyloxy)benzylaminopropanamider som natrium- og/eller calciumkanalselektive modulatorer
EP2575798B1 (en) 2010-06-01 2017-08-09 Rubicon Research Private Limited Gastroretentive dosage forms of gaba analogs
WO2015144825A1 (en) 2014-03-27 2015-10-01 Sanovel Ilac Sanayi Ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression

Also Published As

Publication number Publication date
DK0552240T3 (da) 1998-11-23
DE69129115D1 (de) 1998-04-23
WO1992006686A1 (en) 1992-04-30
EP0552240B1 (en) 1998-03-18
GR3026519T3 (en) 1998-07-31
DE69129115T2 (de) 1998-07-16
CA2092416A1 (en) 1992-04-13
EP0552240A4 (en) 1993-09-01
US5025035A (en) 1991-06-18
JP3192141B2 (ja) 2001-07-23
EP0552240A1 (en) 1993-07-28
MX9101526A (es) 1992-06-05
ATE164065T1 (de) 1998-04-15
JPH06502148A (ja) 1994-03-10

Similar Documents

Publication Publication Date Title
ES2116298T3 (es) Nuevo metodo de tratamiento de la depresion.
DK0429570T3 (da) Osteoinducerende præparater
DE69427869D1 (de) Botulinumtoxine zur behandlung von hyperhydrosis
ES2063912T3 (es) Composiciones inmunogenicas frente a peptidos de gastrina.
ATE150319T1 (de) Behandlung von asthma
HUP9900935A2 (hu) Baktériumellenes és gombaellenes hatású peptid és eljárás az előállítására
ATE40646T1 (de) Verfahren zur pasteurisierung von antihaemophilem kryopraezipitat (ahk) und danach hergestelltes antihaemophiles kryopraezipitat.
DE69227696D1 (de) Zusammensetzungen zur behandlung von hiv-infektionen
HUP9700598A2 (hu) Eljárás hasnyálmirigy-gyulladás megelőzésére és kezelésére alkalmas gyógyszerkészítmény előállítására
DE3854121D1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
DE58907851D1 (de) Verwendung von dimethylpolysiloxan zur behandlung von erkrankungen des gastrointestinaltraktes.
DE69408538D1 (de) Spinnverfahren von polyamiden mittels wässriger abschreckung
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
DE69010294D1 (de) Verwendung von Antiprogestomimetika zur Stimulierung des Eisprungs.
DE69431199D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Schlafstörungen
ES2139573T3 (es) Procedimiento de preparacion industrial de la 4-cloro-3-sulfamoil-n-(2,3-dihidro-2-metil-1h-indol-1-il)-benzamida.
DE69432626D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Desynchronisierungs-Erkankungen
MX9300100A (es) Peptidos hemorreguladores.
DE3856329D1 (de) Verwendung von Ethisterone zur topischen Behandlung von Akne oder androgenetischer Alopezie
ATE107165T1 (de) Verwendung von macrolactonen als antiallergica.
ATE130304T1 (de) Neue alpha-glukosidaseinhibitoren.
NO990436L (no) FremgangsmÕte for behandling av bipolar forstyrrelse
ATE82124T1 (de) Anwendung von n-(2-(diaethylamino)aethyl>-2-methoxy-4((1-h-4,5ihydro-2-imidazolyl)amino>-5- chlorobenzamid als anxiolytisches und antipsychotisches mittel.
DE69731981D1 (de) Neue verbesserte formulierung zur behandlung von thromboembolismus
ATE110385T1 (de) Derivate von aminocarboxylsäure.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 552240

Country of ref document: ES